Medical Oncologist
Biomarker & Molecular Testing
Should I Start Chemotherapy — While Waiting for NGS Results?
Waiting for NGS results when you feel unwell is one of the hardest things a family faces. The honest answer is that sometimes waiting is the right call, and sometimes starting now is. Your oncologist is weighing both, and this page explains what they are looking at.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- Not always a simple choice — Starting chemotherapy now and waiting for NGS results are both defensible options, depending on your clinical situation.
- The cancer type matters most — In some cancers, a targetable mutation found on NGS substantially changes which first-line treatment is recommended.
- How fast it is growing matters — Rapidly progressing cancer may not leave a safe window to wait several weeks for results.
- Starting does not always mean missing out — For many mutations, targeted therapy can still be added or switched to, even after chemotherapy has begun.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Whether to start chemotherapy before your NGS results depends on how fast your cancer appears to be growing, and whether targeted therapy is a realistic option for your cancer type. NCCN and ESMO guidance supports waiting when there is a safe window to do so. Your oncologist will weigh both together.
When is it safe to wait for your NGS results?
Waiting is supported by NCCN and ESMO guidance when the cancer is not growing rapidly, your symptoms are stable, and your cancer type is one where targetable mutations are found in a meaningful proportion of patients.
Lung adenocarcinoma is the clearest example. Alterations such as EGFR, ALK, ROS1 and KRAS G12C have specific approved targeted drugs that are expected to work better first-line than standard chemotherapy. Starting chemotherapy before knowing the mutation status risks using a less effective approach when a targeted option exists.
In cancers where actionable mutations are uncommon — certain pancreatic, gastric or squamous cell histologies — the calculus shifts. Waiting carries less upside, though the NGS result still guides later treatment decisions.
NGS testing takes time. The exact turnaround depends on the laboratory and the panel ordered. Ask your team when your sample was sent and when the result is expected, so you are not waiting without a clear timeline.
What your oncologist is weighing before deciding
- How fast the cancer appears to be growing on recent imaging or blood markers
- Whether your symptoms are getting worse week on week
- Which cancer type and histology you have, and how often actionable mutations appear in it
- Whether standard chemotherapy would change if a targetable mutation is found
- Your fitness and whether a delay could lead to significant clinical deterioration
- The expected laboratory turnaround and whether an expedited panel is available
- Whether a bridging measure — such as supportive care or palliative radiation — could safely manage symptoms while results are awaited
Should I wait or start now? A guide to common situations
| Your situation | If you start chemo now | If you wait for NGS results |
|---|---|---|
| Cancer growing fast, symptoms worsening week on week | Usually the right call — delay may not be clinically safe | Waiting may not be an option |
| Stable symptoms, no sign of rapid progression | Possible, but you may begin the wrong first-line treatment | Safer window to wait; gives results time to shape the plan |
| Lung adenocarcinoma or other cancer type with common actionable mutations | Risk of missing a targeted option that works better first-line | Recommended when clinically safe — NCCN and ESMO guidance supports this |
| Cancer type where targetable mutations are uncommon | Reasonable to proceed | Results still guide later treatment lines, even if not first-line |
| Standard chemotherapy is the same regardless of mutation status | Proceed — results still matter for future decisions | Can proceed; results are less likely to change the immediate plan |
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
What changes if a targetable mutation is found?
If your NGS result shows a targetable mutation, your first-line treatment may change substantially. For some alterations, a targeted oral drug is expected to perform better than chemotherapy and carries a different side-effect profile.
The sequence can matter. Some targeted therapies are most effective when given before chemotherapy rather than after. Starting the wrong treatment first is not always catastrophic — switching is often possible — but acting on the mutation status upfront preserves the most options.
If a result arrives after you have already started chemotherapy, your oncologist will discuss whether to continue, switch, or add the targeted drug. That conversation is still worth having.
Did you know?
For lung adenocarcinoma, NCCN and ESMO guidelines recommend waiting for molecular testing results before starting first-line systemic therapy where it is clinically safe to do so.
Knowing your mutation status upfront means the first treatment you receive is the one most closely matched to your cancer's biology.
Source: NCCN Guidelines for Non-Small Cell Lung Cancer; ESMO Metastatic NSCLC Clinical Practice Guidelines
Questions families ask most about this decision
How long does NGS take, and is there a faster option?
Turnaround time depends on the laboratory, the panel size, and whether the sample must be sent to a reference facility. Comprehensive genomic profiling panels typically take longer than focused panels that cover only the mutations most relevant to your cancer type. Ask your oncologist whether a smaller targeted panel could return a result faster for your situation. In some centres, expedited processing is available for urgent cases. Ask for the expected date in writing so you are not left without a timeline.
Does starting chemotherapy stop me from getting targeted therapy later?
In most cases, no. Targeted therapy can often be substituted or added after a mutation result arrives, and the result remains valid regardless of when it comes. However, for certain mutation types, first-line targeted therapy is expected to work better than giving it after chemotherapy — the sequence matters for those specific alterations. Whether this applies to you depends on which mutation is found and what the evidence says for that alteration. Your oncologist will explain what the sequence means for your situation.
What if I cannot afford to wait — financially or emotionally?
Both are legitimate concerns and your oncologist should hear them. If the wait is clinically safe, a short course of supportive care, steroids or symptom-directed palliative radiation may help you feel more in control while results are awaited — without committing to a full chemotherapy regimen that may need to change. If the financial or emotional cost of uncertainty is very high, say so explicitly at your next appointment. That context helps your team find the right balance rather than making the timing decision in isolation.
What does it mean if my oncologist says the result will not change the first-line plan?
It means that for your specific cancer type and stage, the recommended first-line treatment is the same whether or not a targetable mutation is present. This is common in cancers where chemotherapy, immunotherapy or a combination is standard regardless of molecular findings. Starting now is then a reasonable clinical choice. The NGS result still matters — it guides what happens if the first treatment stops working or if you are considered for a clinical trial later. Ask for that explanation if it has not been offered.
How much does NGS testing cost, and is it covered?
Costs are indicative and vary by panel size, laboratory, and whether reflex testing is included. Comprehensive genomic profiling panels cost more than focused gene panels. In India, some insurers cover molecular testing when it is ordered as part of a treatment decision; others do not, or cover it only for specific cancer types. Ask the diagnostic team for a written cost estimate before the sample is sent, and ask your oncologist or care coordinator which items are likely to be covered under your policy. Any figure quoted should be verified at the time of ordering, as costs change.
Can I get a second opinion on whether to wait or start?
Yes, and for a decision this significant, a second opinion from a centre experienced in your cancer type is reasonable. Bring your pathology report, any recent imaging, and the NGS request form if the test has already been ordered. A second opinion does not mean you are questioning your oncologist — it means you want confidence that the timing decision is right for your specific situation. Most oncologists expect and accept this for complex treatment decisions, particularly when the choice between waiting and starting is genuinely close.
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Is it always wrong to start chemo before NGS results?
No. Starting chemotherapy before NGS results is the right call in some situations — when cancer is growing rapidly, symptoms are worsening, or when standard chemotherapy is the same regardless of mutation status. The question your oncologist is answering is whether the results are likely to change the first-line plan, and whether the clinical situation allows time to find out. In urgent cases, waiting is not safe. In stable cases with a potentially targetable cancer type, waiting is often the better choice.
Which cancer types most often have actionable mutations worth waiting for?
Lung adenocarcinoma is the most established example, where mutations such as EGFR, ALK, ROS1 and KRAS G12C have specific approved targeted therapies. Colorectal cancer, breast cancer and some thyroid cancers also have actionable alterations in a proportion of patients. The answer is specific to your histology — ask your oncologist which mutations your cancer commonly carries and whether any have an approved targeted treatment available.
What if my sample quality is not good enough for NGS?
If the tissue from your biopsy is insufficient or degraded, the laboratory may return an inconclusive result. Your oncologist will then discuss whether a repeat biopsy is feasible, whether a liquid biopsy on a blood sample can substitute for a proportion of the mutations being sought, or whether to proceed with treatment without the molecular information. An inconclusive result is not the same as a negative one — it means the question could not be answered from that sample, not that no mutation exists.
Does NGS testing affect chemotherapy dosing?
Not directly. NGS identifies mutations that guide which treatment is used, not the dose of chemotherapy. Dosing is calculated from your weight, kidney and liver function, and the treatment protocol. What NGS can determine is whether you should be on chemotherapy at all for first-line treatment, or whether a targeted drug is a better fit. If a targeted agent is indicated, it replaces or modifies the regimen rather than adjusting a chemotherapy dose.
Can CION coordinate NGS testing and treatment together?
Yes. Your oncologist at a CION centre can order molecular testing and coordinate results alongside your treatment planning. Chemotherapy and immunotherapy, where indicated, are given as day care. PET-CT and response-assessment imaging are coordinated with partner imaging centres. If your results indicate a specific targeted therapy, your oncologist will explain whether it is available and how it fits into your plan.
What should I ask at my next appointment about this decision?
Ask three questions: first, whether my cancer type commonly has targetable mutations that would change first-line treatment. Second, whether my clinical situation allows a safe window to wait for the result. Third, if treatment starts now and a mutation is found later, what are the options for changing or adding to the plan. Write the answers down — these are the three things that shape the timing decision, and having them clearly stated helps you make sense of what you have been told.